ADEL与赛诺菲签署了一项价值10.4亿美元的全球许可协议,涉及新型阿尔茨海默病研究性疗法ADEL-Y01ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy

动脉网
Dec 16, 2025

ADEL, Inc., a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases such as Alzheimer's Disease, today announced that it has entered into an exclusive worldwide ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10